“The selling restriction of generics can cause the social benefit cost worth between KRW 2.4 billion and KRW 4.1 billion”

As the Patent Linkage System will be fully enforced on 15^th next month, it is analyzed that companies having original products will get reflected benefits worth of KRW 3.2 billion at most every year through the newly appointed generic ‘selling restriction’ measure.

Considering the market penetration ratio of generics, additionally,it is estimated that cost, approximately KRW 4.1 billion,will b...